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not able to form new tumors and have high expression of 
CD127 on their T cells, a marker for immunological memory. 
This new treatment will be further investigated in a Phase I 
study for patients with an oligometastatic solid tumor 
(NCT02086721). 
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Purpose or Objective: The novel combretastatin analogue, 
OXi4503, is a vascular disrupting agent (VDA) that has 
recently been shown to significantly enhance a stereotactic 
radiation treatment. This was achieved using an OXi4503 dose 
of 10 mg/kg combined with a stereotactic treatment of 3 x 
15 Gy. The current study was undertaken to determine the 
OXi4503 dose dependency when using different stereotactic 
radiation dose schedules. 
 
Material and Methods: A C3H mammary carcinoma grown in 
the right rear foot of female CDF1 mice was used in all 
experiments. Treatments were performed in restrained non-
anaesthetised animals when tumours had reached 200 cubic 
mm in size. Tumours were locally irradiated (230 kV x-rays) 
with 3 fractions of radiation varying from 5-20 Gy (each 
fraction given with an interval of 2-3 days over a one week 
period). OXi4503 was dissolved in saline prior to each 
experiment; once prepared it was kept cold and protected 
from light. Various doses (5-25 mg/kg) were intraperitoneally 
injected into mice 1-hour after each irradiation treatment. 
Three days after the final irradiation the tumours were 
subjected to a clamped top-up dose which involved giving 
graded radiation doses with the tumour bearing leg clamped 
for 5 minutes before and during irradiation. The percentage 
of mice in each treatment group showing local tumour 
control 90 days after irradiating was then recorded. Following 
logit analysis of the clamped top-up radiation dose response 
curves, the TCD50 values (radiation dose to control 50% of 
tumours) were estimated. A Chi-squared test (p<0.05) was 
used to determine significant differences between the TCD50 
values. 
 
Results: The clamped top-up TCD50 values (with 95% 
confidence intervals) obtained following irradiation with 3 
treatments of 10, 15 or 20 Gy were found to be 42 Gy (38-
47), 30 Gy (23-39), and 0.8 Gy (0.3-2.3), respectively. A plot 
of the TCD50 values against the stereotactic doses gave rise 
to a linear response (slope = -4.1; correlation coefficient = 
0.97). OXi4503 significantly decreased the clamped radiation 
top-up TDC50 values and this affect appeared to be 
independent of both the ambient radiation dose applied with 
each of the 3 fractions and the VDA dose; the curve showing 
the TCD50 values against stereotactic radiation dose was 
similar to that for radiation alone (slope = -4.3; correlation 
coefficient = 0.94), but the radiation + OXi4503 curve was 
some 15 Gy lower than the radiation only curve. 
 
Conclusion: OXi4503 is an effective agent for enhancing a 
stereotactic radiation treatment. But, the enhanced response 
appeared to be a simple additive effect independent of both 
the radiation dose applied with each fraction and the VDA 
dose used. 
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Purpose or Objective: Hypoxia is a common feature of solid 
tumors. Conventional treatments such as chemo- and 
radiotherapy (RT) are less effective against hypoxic tumor 
cells. Hypoxia-activated prodrugs (HAPs) are specifically 
activated in hypoxia to target hypoxic cells as well as 
adjacent oxygenated tumor cells via their bystander effect. 
DTP-006 is a newly synthesized nitroaromatic HAP with highly 
favorable properties: 1) activation under hypoxia, 2) high 
bystander effect, 3) excellent aqueous solubility, 4) murine 
oral bioavailability and 5) no off-mechanism activation by 
human aerobic reductases NQO1 and AKR1C3. Here we show 
the effects of DTP-006 on tumor cell viability, spheroid 
growth and radiation resistant tumor cells in vivo, and assess 
its pharmacokinetics and oral bioavailability in mice. 
 
Material and Methods: The one-electron reduction potential 
(E1) of DTP-006 was determined by pulse and steady state 
radiolysis. IC50 viability ratios were assessed in 2D cell 
culture exposed to normoxic or anoxic (≤0.0 2% O2) 
conditions. H460 multicellular layers (MCLs) under aerobic 
(5% CO2, 95% O2) or anoxic (5% CO2, 95% N2) conditions were 
incubated with DTP-006 for 5 h after which cells were plated 
for clonogenic survival. H460 spheroids were incubated with 
DTP-006 upon confirmation of a hypoxic core. NIH-III mice 
bearing H460 tumors received a single i.p. dose of DTP-006 
(781 mg/kg) after irradiation (10 Gy) of tumors. 18 h later 
tumors were excised and single cell suspensions were 
generated and plated for clonogenic survival. Tumor-free 
female NIH-III mice received a single i.v. or oral dose of DTP-
006 (383 mg/kg). Terminal blood samples collected at time 
points via cardiocentesis were analyzed by LC/MS/MS. Plasma 
half-life (T1/2) and absolute oral bioavailability (Fabs) were 
calculated. 
 
Results: DTP-006 has an E1 value of -351 mV, indicating 
strong oxygen inhibition of nitro radical formation. IC50 were 
lower in anoxia than normoxia by factors of 203 (MDA-MB-
468), 55 (C33A), and 20 (HCT116). In a H460 MCL clonogenic 
assay, 100 µM DTP-006 caused 99% cell kill under anoxia but 
exhibited no aerobic cell kill. It caused a concentration-
dependent growth delay in spheroids, where 250 µM 
completely halted growth. A single dose of DTP-006 caused a 
significant loss of clonogenicity when combined with RT in an 
in vivo excision assay (log cell kill 2.35 relative to control). 
T1/2 after oral administration was 0.82 h and bioavailability 
was 47%. 
 
Conclusion: DTP-006 kills tumor cells only in severe hypoxic 
conditions in vitro, reduces growth of tumor cell spheroids, 
and sterilizes radiation resistant tumor cells in vivo. It has 
clinically relevant bioavailability after oral administration. As 
such, DTP-006 is a promising new HAP with potentially 
favorable properties for clinical use. Further studies to 
determine the antitumor effects of DTP-006 as a 
monotherapy and in combination with RT in several 
preclinical tumor models are ongoing. 
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